CLDX241115C60000
- 0.33
- 0.000.00%
Celldex Therapeutics Newsroom
Guggenheim Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Announces Target Price $90
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $44 to $78
Celldex Therapeutics (NASDAQ:CLDX) Pulls Back 6.1% This Week, but Still Delivers Shareholders Fantastic 57% CAGR Over 5 Years
Celldex: Barzolvolimab has reached the endpoint in chronic urticaria research.
Biopharmaceutical company Celldex Therapeutics announced that in the study of chronic inducible urticaria, Barzolvolimab achieved all primary and secondary endpoints with high statistical significance. Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab is specifically and effectively inhibiting the activation of KIT. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria. According to a report
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints With High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results From Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
Express News | Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results From Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at Acaai 2024
Celldex Therapeutics, Inc. (CLDX): Hedge Funds' Hidden Gem in Small-Cap Stocks
Goldman Sachs Maintains Celldex Therapeutics(CLDX.US) With Hold Rating, Maintains Target Price $45
Jasper Gains 11% on Data for Briquilimab in Urticaria
Citi Initiates Celldex Therapeutics(CLDX.US) With Buy Rating, Announces Target Price $70
Celldex (CLDX) Gets a Buy From Citi
Celldex Started by Goldman Sachs at Neutral, Lack of Catalysts Cited
Celldex Therapeutics Initiated at Neutral by Goldman Sachs
Celldex Therapeutics Analyst Ratings
Goldman Sachs Initiates Celldex Therapeutics(CLDX.US) With Hold Rating, Announces Target Price $45
Hold Rating on Celldex Therapeutics Amid Drug Development Prospects and Competitive Challenges
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Leerink Partners Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $78